Recent blog posts
NCT07407673 AMDINOCILLIN PIVOXIL Bacterial urinary infection Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07407673 AMDINOCILLIN PIVOXIL Bacterial urinary infection Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07407673 clinical trial report covering AMDINOCILLIN PIVOXIL, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07409272 Leucovorin Calcium Pancreatic adenocarcinoma metastatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07409272 Leucovorin Calcium Pancreatic adenocarcinoma metastatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07409272 clinical trial report covering Leucovorin Calcium, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07412132 Lacosamide Bipolar Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07412132 Lacosamide Bipolar Disorder Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07412132 clinical trial report covering Lacosamide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07410117 Cenvacibart Thrombosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07410117 Cenvacibart Thrombosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07410117 clinical trial report covering Cenvacibart, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07409428 HMPL-760 Diffuse large B-cell lymphoma recurrent Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07409428 HMPL-760 Diffuse large B-cell lymphoma recurrent Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07409428 clinical trial report covering HMPL-760, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07412236 Hydronidone Hepatitis B, Chronic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07412236 Hydronidone Hepatitis B, Chronic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07412236 clinical trial report covering Hydronidone, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07412756 Brenipatide Depressive Disorder, Major Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07412756 Brenipatide Depressive Disorder, Major Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07412756 clinical trial report covering Brenipatide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07416110 Human rabies vaccine (serum-free Vero cells)(Chengdu Biotec) Rabies Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07416110 Human rabies vaccine (serum-free Vero cells)(Chengdu Biotec) Rabies Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07416110 clinical trial report covering Human rabies vaccine (serum-free Vero cells)(Chengdu Biotec), Phase 3, endpoints, sponsor, geography, readout ti
Read →
NCT07414706 Ropivacaine Hydrochloride Toxicity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07414706 Ropivacaine Hydrochloride Toxicity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07414706 clinical trial report covering Ropivacaine Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07414394 Tigulixostat Gout Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07414394 Tigulixostat Gout Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07414394 clinical trial report covering Tigulixostat, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07412613 Cadonilimab Microsatellite instability-high colorectal cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07412613 Cadonilimab Microsatellite instability-high colorectal cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07412613 clinical trial report covering Cadonilimab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07415252 Herpes zoster vaccine (SK Chemicals) Chickenpox Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07415252 Herpes zoster vaccine (SK Chemicals) Chickenpox Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 August 2026
NCT07415252 clinical trial report covering Herpes zoster vaccine (SK Chemicals), Phase 3, endpoints, sponsor, geography, readout timing and development whi
Read →